WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of GeneDx Holdings Corp. (NASDAQ: WGS) between April 16, 2025 and May 4, 2026, inclusive ...
All 63 donor-recipient pairs enrolled and treated according to protocol across multiple clinical centersRandomized, controlled Phase IIb trial evaluating TolerogenixX’s proprietary MIC technology, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results